SCHEMBL6418795

SCHEMBL6418795

CN1C(=O)c2ccc(Cl)cc2C(C(=O)NCC2CC2)C1c1cc(C(F)(F)F)cc(C(F)(F)F)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.41
POLB P06746 1/20 0.41
CYP3A4 P08684 2/20 0.38
CYP2C9 P11712 2/20 0.38
KCNH2 Q12809 1/20 0.38
CACNA1I Q9P0X4 1/20 0.38
CYP2C19 P33261 1/20 0.38
ALDH1A1 P00352 3/20 0.37
HTT P42858 2/20 0.37
P2RX7 Q99572 2/20 0.37
GLA P06280 1/20 0.36
CASP1 P29466 1/20 0.36
LMNA P02545 2/20 0.36
KDM4E B2RXH2 1/20 0.36
MAPT P10636 1/20 0.36
MAPK1 P28482 1/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
GRM5 P41594 1/20 0.35
CETP P11597 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6413426 0.90 POLB (0.42) TSHRPOLBCYP3A4CYP2C9KCNH2
SCHEMBL6412345 0.88 GLA (0.47) TSHRPOLBALDH1A1HTTP2RX7
SCHEMBL6418372 0.84 LMNA (0.47) TSHRPOLBALDH1A1HTTGLA
SCHEMBL6412309 0.82 LMNA (0.45) TSHRPOLBKCNH2CACNA1IALDH1A1
SCHEMBL6417300 0.77 TACR2 (0.43) TSHRCYP3A4CYP2C9CYP2C19ALDH1A1
SCHEMBL6416797 0.77 GAA (0.44) TSHRPOLBCYP3A4CYP2C9CYP2C19
SCHEMBL6412294 0.77 TSHR (0.50) TSHRPOLBCYP3A4CYP2C9ALDH1A1
SCHEMBL6416816 0.76 LMNA (0.64) TSHRPOLBCYP3A4CYP2C9KCNH2
SCHEMBL6415492 0.74 GLA (0.53) TSHRALDH1A1HTTGLACASP1
SCHEMBL6413399 0.74 GLA (0.53) TSHRALDH1A1HTTGLACASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050124614-A1 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis AXYS PHARMACEUTICALS, INC. (US) 2005-06-09 US claimed
WO-2004004727-A1 3,4-DIHYDROISOQUINOLIN-1-ONE DERIVATIVES AS INDUCERS OF APOPTOSIS AXYS PHARMACEUTICALS, INC. (US) 2004-01-15 WO claimed
US-20050124614-A1 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis AXYS PHARMACEUTICALS, INC. (US) 2005-06-09 US disclosed
WO-2004004727-A1 3,4-DIHYDROISOQUINOLIN-1-ONE DERIVATIVES AS INDUCERS OF APOPTOSIS AXYS PHARMACEUTICALS, INC. (US) 2004-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124614-A1 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis CASP3, BAX, BAD TSHR 4878/4885POLB 2345/4885CYP3A4 162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.